Presentation description

Peptides as therapeutics face challenges due to poor bioavailability and susceptibility to proteolytic degradation. Modifying bioactive peptides through residue modification, cyclization, and polycyclization are proven strategies to address these issues. Roberts group has developed a site-selective oxidation method utilizing TAD peptide intermediates. I am advancing this method by developing an arylomycin mimic, modify the natural product to act against gram-negative bacteria.